FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
18/07/2022
Voltar para busca
Dado oficial do USPTO
BRIGHT PEAK
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
42
Atualização mais recente
18/07/2022
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
25/03/2020
Data de registro
11/01/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
11/01/2022
Última transação
11/01/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
CH
Examinador
LAM, HAI-LY HUYNH
Unidade examinadora
N10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Bright Peak Therapeutics AG
Representantes
Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the treatment and prevention of cancerautoimmune diseasesinfectious and parasitic diseasesneoplasmsdiseases of the blood and blood-forming organsendocrine diseasesnutritional and metabolic diseasesmental and behavioral disordersdiseases of the nervous systemeye and adnexaear and mastoid process disordersdiseases of the circulatory systemrespiratory systemdigestive systemskin and subcutaneous tissue disordersdiseases of the musculoskeletal system and connective tissuediseases of the genitourinary systemdisorders and abnormalities relating to pregnancy and childbirthcertain conditions originating in the puerperium and perinatal periodscongenital malformations and deformationschromosomal abnormalities; medical and veterinary preparationsrecombinant or chemically synthesized and optimized proteins; preparations for destroying vermin; fungicidesherbicides; biotechnological preparationsrecombinant or chemically synthesized and optimized proteins for medical use; enzymes for medical use; enzymes for veterinary use; biological and chemical reagents for medical or veterinary use; amino acids for medical use; amino acids for veterinary use; peptides for medical or veterinary usefor the treatment of cancerautoimmune diseasesinfectious and parasitic diseasesneoplasmsdiseases of the blood and blood-forming organsendocrine diseasesnutritional and metabolic diseasesmental and behavioral disordersdiseases of the nervous systemeye and adnexaear and mastoid process disordersdiseases of the circulatory systemrespiratory systemdigestive systemskin and subcutaneous tissue disordersdiseases of the musculoskeletal system and connective tissuediseases of the genitourinary systemdisorders and abnormalities relating to pregnancy and childbirthcertain conditions originating in the puerperium and perinatal periodscongenital malformations and deformationschromosomal abnormalities; proteins for medical or veterinary userecombinant or chemically synthesized and optimized proteins for detection and treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disordersautoimmune diseasesinfectious and parasitic diseasesneoplasmsdiseases of the blood and blood-forming organsnutritional diseasesmental and behavioral disordersdiseases of the nervous systemeye and adnexaear and mastoid process disordersdiseases of the circulatory system and digestive systemskin and subcutaneous tissue disordersdiseases of the musculoskeletal system and connective tissuedisorders and abnormalities relating to pregnancy and childbirthcertain conditions originating in the puerperium and perinatal periodscongenital malformations and deformationschromosomal abnormalities; pharmaceutical preparations for cancer treatment; biopharmaceutical preparations for cancer treatment; pharmaceutical compositions and preparations for cancer prevention and treatment; pharmaceutical preparations for treatment of autoimmune and inflammatory diseases; pharmaceutical preparations for treatment of skin diseases; pharmaceutical preparations for treatment of neurodegenerativemetabolic and ophthalmological diseases
Classe 42
Scientific and technological servicesscientific researchscientific analysisscientific testing in the field of biotechnology and new product research and design services relating thereto; research and development in the field of biotechnology; consulting services in the field of biotechnology; scientific research services in the field of proteinspeptides and antibodiesscientific advice relating thereto; scientific research services for medical purposes in the field of cancer and autoimmune diseases and scientific advice relating thereto
Publicações
Histórico de despachos e eventos da marca no USPTO.
42 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
23/06/2022
FIMP
FINAL DISPOSITION PROCESSED
22/06/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/04/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
11/01/2022
GPNX
NOTIFICATION PROCESSED BY IB
04/11/2021
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
03/11/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
26/10/2021
PUBO
PUBLISHED FOR OPPOSITION
26/10/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
13/10/2021
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
13/10/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/10/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
06/10/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/10/2021
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
17/09/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/09/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
24/08/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
24/08/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
24/08/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
24/08/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
29/07/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
29/07/2021
ALIE
ASSIGNED TO LIE
27/07/2021
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
22/07/2021
EXPI
EX PARTE APPEAL-INSTITUTED
22/07/2021
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
22/07/2021
EXAF
EXPARTE APPEAL RECEIVED AT TTAB
22/07/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
26/01/2021
GNFR
FINAL REFUSAL E-MAILED
26/01/2021
CNFR
FINAL REFUSAL WRITTEN
26/01/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/01/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/01/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/01/2021
RFNT
REFUSAL PROCESSED BY IB
07/08/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
23/07/2020
RFRR
REFUSAL PROCESSED BY MPU
23/07/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
18/06/2020
CNRT
NON-FINAL ACTION WRITTEN
17/06/2020
DOCK
ASSIGNED TO EXAMINER
16/06/2020
MAFR
APPLICATION FILING RECEIPT MAILED
12/05/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/05/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/05/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BRIGHT PEAK ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.